Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
1.
ESMO Open ; 9(3): 102388, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38442452

RESUMO

BACKGROUND: The HER2DX risk-score has undergone rigorous validation in prior investigations involving patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer. In this study, we present the outcomes of the HER2DX risk-score within the most recent release of the Sweden Cancerome Analysis Network-Breast (SCAN-B) HER2+ cohort. This updated examination benefits from a larger patient sample, an extended follow-up duration, and detailed treatment information. MATERIALS AND METHODS: Clinical and RNAseq data from the SCAN-B dataset were retrieved from Gene Expression Omnibus (GSE81538). Among the 6600 patients, 819 had HER2+ breast cancer, with 757 individuals with research-based HER2DX risk-scores and corresponding survival outcomes. The HER2DX risk-score was evaluated (i) as a continuous variable and (ii) using predefined cut-offs. The primary endpoint for this study was overall survival (OS). The Kaplan-Meier method and Cox models were used to estimate OS and a multistate model with four states was fitted to better characterize patients' follow-up. RESULTS: The median follow-up time was 7.5 years (n = 757). The most common systemic therapy was chemotherapy with trastuzumab (82.0%) and most tumors were classified as T1-T2 (97.1%). The HER2DX risk-score as a continuous variable was significantly associated with OS after adjustment for clinical variables and treatment regimen [hazard ratios (HR) per 10-unit increment = 1.31, 95% confidence interval (CI) 1.13-1.51, P < 0.001] as well as within predefined risk groups (high versus low; HR = 2.57, 95% CI 1.36-4.85, P < 0.001). Patients classified as HER2DX high-risk also had higher risk of (i) breast cancer recurrence and (ii) death without previous recurrence. Within the subgroup of HER2+ T1N0 tumors (n = 297), those classified as high-risk demonstrated inferior OS compared to low-risk tumors (7-year OS 77.8% versus 96.8%, P < 0.001). The HER2DX mRNA ERBB2 score was associated with clinical HER2 status (area under the receiver operating characteristic curve = 0.91). CONCLUSIONS: In patients with early-stage HER2+ breast cancer, HER2DX risk-score provides prognostic information beyond clinicopathological variables, including treatment regimen with or without trastuzumab.


Assuntos
Neoplasias da Mama , Humanos , Feminino , Neoplasias da Mama/tratamento farmacológico , Prognóstico , Suécia/epidemiologia , Recidiva Local de Neoplasia/tratamento farmacológico , Trastuzumab/farmacologia , Trastuzumab/uso terapêutico
2.
Ann Oncol ; 34(9): 783-795, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37302750

RESUMO

BACKGROUND: The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status. MATERIALS AND METHODS: Seven neoadjuvant cohorts with HER2DX and clinical individual patient data were evaluated (DAPHNe, GOM-HGUGM-2018-05, CALGB-40601, ISPY-2, BiOnHER, NEOHER and PAMELA). All patients were treated with neoadjuvant trastuzumab (n = 765) in combination with pertuzumab (n = 328), lapatinib (n = 187) or without a second anti-HER2 drug (n = 250). Event-free survival (EFS) and overall survival (OS) outcomes were available in a combined series of 268 patients (i.e. NEOHER and PAMELA) with a pCR (n = 118) and without a pCR (n = 150). Cox models were adjusted to evaluate whether HER2DX can identify patients with low or high risk beyond pCR status. RESULTS: HER2DX pCR score was significantly associated with pCR in all patients [odds ratio (OR) per 10-unit increase = 1.59, 95% confidence interval 1.43-1.77; area under the ROC curve = 0.75], with or without dual HER2 blockade. A statistically significant increase in pCR rate due to dual HER2 blockade over trastuzumab-only was observed in HER2DX pCR-high tumors treated with chemotherapy (OR = 2.36 (1.09-5.42). A statistically significant increase in pCR rate due to multi-agent chemotherapy over a single taxane was observed in HER2DX pCR-medium tumors treated with dual HER2 blockade (OR = 3.11, 1.54-6.49). The pCR rates in HER2DX pCR-low tumors were ≤30.0% regardless of treatment administered. After adjusting by pCR status, patients identified as HER2DX low-risk had better EFS (P < 0.001) and OS (P = 0.006) compared with patients with HER2DX high-risk. CONCLUSIONS: HER2DX pCR score and risk score might help identify ideal candidates to receive neoadjuvant dual HER2 blockade in combination with a single taxane in early-stage HER2+ breast cancer.


Assuntos
Neoplasias da Mama , Humanos , Feminino , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/genética , Neoplasias da Mama/patologia , Receptor ErbB-2/genética , Resultado do Tratamento , Trastuzumab , Taxoides , Terapia Neoadjuvante/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
3.
J Healthc Qual Res ; 38(1): 43-49, 2023.
Artigo em Espanhol | MEDLINE | ID: mdl-35739039

RESUMO

INTRODUCTION: Crisis caused by the SARS-CoV-2 virus limit face-to-face consultation to the minimum necessary, this was a change toward telephone activity. OBJECTIVE: To analyze the experience of a neuropediatric consultation, INRPC, and satisfaction survey with the telephone consultation during COVID-19 crisis. MATERIAL AND METHODS: Observational, cross-sectional, descriptive and analytical study of healthcare activity, as well as user satisfaction, during the State of Alarm in a neuropediatric consultation in a regional referral hospital. To measure satisfaction, a survey is conducted with parents and guardians. RESULTS: 416 children were attended by telephone. Most frequent diagnoses: neurodevelopmental disorder (27.8%), isolated ADD/ADHD (26.8%), and epilepsy (9.2%). 32.2% responded to the survey: 66.6% prior satisfaction. Global satisfaction with telephone consultation 59.9%; 77% would return to make the telephone consultation. CONCLUSIONS: User satisfaction with the telephone consultation, in a crisis situation, is similar to that perceived with the face-to-face consultation. 32% respond to the survey, and 60% are satisfied.


Assuntos
COVID-19 , Criança , Humanos , COVID-19/epidemiologia , Encaminhamento e Consulta , Estudos Transversais , SARS-CoV-2 , Telefone , Satisfação Pessoal
4.
Neurocirugía (Soc. Luso-Esp. Neurocir.) ; 33(4): 157-164, jul. - ago. 2022. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-204449

RESUMO

Introduction and objective: Arachnoid cysts (ACs) are relatively frequent lesions related to different neurological symptoms, being mostly incidentally diagnosed. This study aims to clarify whether AC surgery in epileptic patients is useful in their treatment. Material and methods: The patients registered in the database of the Neuropediatrics Section from May 1990 to August 2019 are analyzed retrospectively. Patients in whom the diagnosis of ACs and epilepsy coincide are studied. The location, size and number of ACs, neurological development, age at diagnosis, follow-up time, the performance of surgery on the cyst, evolution, anatomical relationship between brain electrical activity and location of AC, and type of epilepsy are analyzed. Results: After analyzing the database, we found 1881 patients diagnosed with epilepsy, of which 25 had at least one intracranial AC. In 9 of the patients, cerebral or genetic pathologies were the cause of epilepsy. Of the other 16, only 2 patients showed that the type of epilepsy and the epileptogenic focus coincided with the location of the AC; one of them was surgically treated without success, and the other one remained asymptomatic without receiving medical or surgical treatment(AU)


Introducción y objetivo: Los quistes aracnoideos (QAs) son lesiones relativamente comunes relacionados con diferentes síntomas neurológicos, siendo diagnosticados de forma incidental en su mayoría. Este estudio tiene como objetivo aclarar si la cirugía sobre el QA en pacientes epilépticos es útil en su tratamiento. Material y métodos: Se analizan retrospectivamente los pacientes registrados en la base de datos de la Sección de Neuropediatría desde mayo de 1990 a agosto de 2019. Se estudian los pacientes en los que coincide el diagnóstico de QA y epilepsia. Se analiza la localización, tamaño y número de los QA, el desarrollo neurológico, edad al diagnóstico, tiempo de seguimiento, realización de cirugía sobre el QA, evolución, relación anatómica entre la actividad eléctrica cerebral y la localización del QA, así como el tipo de epilepsia. Resultados: Tras el análisis de la base de datos encontramos 1.881 pacientes diagnosticados de epilepsia, entre ellos 25 con al menos un QA intracraneal. En nueve de los pacientes la patología cerebral o genética por sí misma era causa de epilepsia. De los otros 16, únicamente en dos casos se evidenció que el tipo de epilepsia y el foco epileptogénico coincidían con la localización del QA; uno de ellos fue tratado quirúrgicamente sin éxito y el otro permaneció asintomático sin recibir tratamiento médico ni quirúrgico. Conclusiones: Aunque es necesario diseñar un estudio prospectivo para establecer causalidad, los resultados de nuestro trabajo y la literatura disponible sugieren que no hay relación causal entre la presencia de QAs y epilepsia. El estudio y tratamiento de estos pacientes debería ser completado en una unidad multidisciplinar de cirugía de la epilepsia, sin asumir de inicio que el QA es la causa de la epilepsia(AU)


Assuntos
Humanos , Criança , Cistos Aracnóideos/complicações , Cistos Aracnóideos/cirurgia , Epilepsia/etiologia , Epilepsia/cirurgia
5.
Neurologia (Engl Ed) ; 37(5): 325-333, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-35672119

RESUMO

INTRODUCTION: Neurofibromatosis type 1 (NF1) is a progressive multisystem disorder following an autosomal dominant inheritance pattern that presents with multiple neurological manifestations. METHODS: We reviewed medical histories of patients with NF1 followed up at our hospital's paediatric neurology department from May 1990 to 31 December 2018. We collected data on neurological symptoms. RESULTS: A total of 128 patients with NF1 were identified. Mean age (SD) at NF1 diagnosis was 4.43 (3.38) years (range, 0.5-14.5 years). There was a slight female predominance (53.1%). Macrocephaly (head circumference over 2 SDs above average for age) was present in 37.5% of cases. Attention-deficit/hyperactivity disorder was recorded in 28.9% of patients (37): combined type in 20 patients, predominantly inattentive in 15, and predominantly impulsive/hyperactive in 2. Other manifestations included headache (18.6%), cognitive impairment (7.8%), motor deficit (6.2%), and epilepsy (4.68%). Brain MRI was performed in 85 patients, revealing T2-weighted hyperintensities in the basal ganglia and/or cerebellum in 60 patients (70.5%), Chiari malformation type 1 in 4 cases, and arachnoid cysts in 3. Optic nerve gliomas were identified by MRI in 22 patients (25.8%). Other MRI findings included plexiform neurofibromas (9.3%) and central nervous system gliomas (3.1%). CONCLUSIONS: The neurological manifestations identified in our sample are consistent with those reported in the literature. Effective transfer strategies from paediatric neurology departments and subsequent clinical follow-up by adult neurology departments are needed to prevent loss to follow-up in adulthood.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Epilepsia , Neurofibromatose 1 , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Cefaleia , Humanos , Lactente , Imageamento por Ressonância Magnética , Masculino , Neurofibromatose 1/complicações
6.
Neurología (Barc., Ed. impr.) ; 37(5): 325-333, Jun. 2022. tab
Artigo em Inglês, Espanhol | IBECS | ID: ibc-205982

RESUMO

Introducción: La neurofibromatosis tipo 1 (NF1) es un desorden progresivo multisistémico de herencia autosómica dominante que presenta numerosas manifestaciones neurológicas. Métodos: Revisión de historias clínicas de pacientes afectos de NF1 controlados en una Unidad de Neuropediatría de mayo de 1990 a 31 de diciembre de 2018 y sus manifestaciones neurológicas asociadas. Resultados: Se revisaron 128 pacientes afectos de NF1. Edad media al diagnóstico de NF1, 4,43 años ± 3,38 SDS (rango 6 meses-14,5 años) con discreto predominio femenino (53,1%). Se asocia macrocefalia (PC> 2SDS) en el 37,5% de los casos. TDAH en el 28,9% de los casos (37), subtipo combinado 20, inatento 15 casos y predominantemente hiperactivo 2 casos. Otras manifestaciones incluyen; cefalea (18,7%), déficit cognitivo (7,8%), afectación motora (6,2%) y epilepsia (4,68%). Se realizó RM cerebral a 85 pacientes, mostrando 60 (70,5%) hiperseñales en T2 en ganglios basales y/o cerebelo, junto con otras alteraciones como Chiari I (4 casos) y quistes aracnoideos (3 casos). Se identificaron gliomas de nervio óptico en 22 casos (25,8%). Otros hallazgos diagnosticados por RM incluyen neurofibromas plexiformes (9,3%) y otros gliomas localizados en sistema nervioso central (3,1%). Conclusiones: Las manifestaciones neurológicas encontradas concuerdan con lo recogido en la literatura. El seguimiento de estos pacientes se pierde en la edad adulta, siendo necesario establecer adecuadas estrategias de transferencia y posterior seguimiento de pacientes a los servicios de adultos. (AU)


Introduction: Neurofibromatosis type 1 (NF1) is a progressive multisystem disorder following an autosomal dominant inheritance pattern that presents with multiple neurological manifestations. Methods: We reviewed medical histories of patients with NF1 followed up at our hospital's paediatric neurology department from May 1990 to 31 December 2018. We collected data on neurological symptoms. Results: A total of 128 patients with NF1 were identified. Mean age (SD) at NF1 diagnosis was 4.43 (3.38) years (range, 0.5-14.5 years). There was a slight female predominance (53.1%). Macrocephaly (head circumference over 2 SDs above average for age) was present in 37.5% of cases. Attention-deficit/hyperactivity disorder was recorded in 28.9% of patients (37): combined type in 20 patients, predominantly inattentive in 15, and predominantly impulsive/hyperactive in 2. Other manifestations included headache (18.6%), cognitive impairment (7.8%), motor deficit (6.2%), and epilepsy (4.68%). Brain MRI was performed in 85 patients, revealing T2-weighted hyperintensities in the basal ganglia and/or cerebellum in 60 patients (70.5%), Chiari malformation type 1 in 4 cases, and arachnoid cysts in 3. Optic nerve gliomas were identified by MRI in 22 patients (25.8%). Other MRI findings included plexiform neurofibromas (9.3%) and central nervous system gliomas (3.1%). Conclusions: The neurological manifestations identified in our sample are consistent with those reported in the literature. Effective transfer strategies from paediatric neurology departments and subsequent clinical follow-up by adult neurology departments are needed to prevent loss to follow-up in adulthood. (AU)


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Adulto Jovem , Adulto , Transtorno do Deficit de Atenção com Hiperatividade , Epilepsia , Neurofibromatose 1/complicações , Imageamento por Ressonância Magnética , Cefaleia , Glioma do Nervo Óptico
7.
NPJ Precis Oncol ; 5(1): 23, 2021 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-33742063

RESUMO

Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well as its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes in tumour-immune contexture, as assessed by stromal tumour-infiltrating lymphocytes (sTILs) and by multiplexed spatial cellular phenotyping, during treatment with lapatinib-trastuzumab in HER2+ BC patients (PAMELA trial). Moreover, we evaluate the relationship of tumour-immune contexture with hormone receptor status, intrinsic subtype and immune-related gene expression. sTIL levels increase after 2 weeks of HER2 blockade in HR-negative disease and HER2-enriched subtype. This is linked to a concomitant increase in cell density of all four immune subpopulations (CD3+, CD4+, CD8+, Foxp3+). Moreover, immune contexture analysis showed that immune cells spatially interacting with tumour cells have the strongest association with response to anti-HER2 treatment. Subsequently, sTILs consistently decrease at the surgery in patients achieving pathologic complete response, whereas most residual tumours at surgery remain inflamed, possibly reflecting a progressive loss of function of T cells. Understanding the features of the resulting tumour immunosuppressive microenvironment has crucial implications for the design of new strategies to de-escalate or escalate systemic therapy in early-stage HER2+ BC.

8.
Neurología (Barc., Ed. impr.) ; 35(6): 381-394, jul.-ago. 2020. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-197809

RESUMO

INTRODUCCIÓN: La enfermedad neurológica representa una parte importante en las unidades de cuidados intensivos pediátricos (UCIP) y es causa de morbimortalidad. El objetivo de este trabajo es analizar la evolución funcional del niño crítico con enfermedad neurológica. MATERIAL Y MÉTODO: Estudio retrospectivo descriptivo, de niños con enfermedad neurológica ingresados en una UCIP durante 3 años (2012-2014), valorando pronóstico vital y funcional, al alta y al año del ingreso, según las Categorías de estado general y cerebral pediátrico (CEGP-CECP) y la Escala de estado funcional (FSS). Los resultados se comparan con nuestros datos previos (años 1990-1999) y con los del estudio multicéntrico internacional PANGEA. RESULTADOS: Se estudió a 266 niños. La mortalidad fue del 3%, sin que los modelos PRISM-II y PIM2 muestren capacidad predictiva. La salud funcional refleja empeoramiento clínicamente significativo al alta de UCIP, en el 30% según CEGP, en el 15% según CECP y en el 5% según FSS. Transcurrido un año, la funcionalidad mejora según CEGP-CECP, pero no según FSS. Los niños sin enfermedad neurológica de base presentan afectación funcional en mayor porcentaje, que se mantiene en el tiempo. Comparada con nuestros datos previos, la mortalidad global y neurocrítica disminuye (5,60 vs. 2,1%; p = 0,0003 y 8,44 vs. 2,63%; p = 0,0014, respectivamente). En relación con el estudio multicéntrico PANGEA, tanto la mortalidad como el empeoramiento funcional cerebral del niño neurocrítico son menores en el estudio actual (1,05 vs. 13,32%; p < 0,0001 y 10,47 vs. 23,79%; p < 0,0001, respectivamente). CONCLUSIONES: Alrededor de un tercio de los niños críticos muestran enfermedad neurológica. Un porcentaje importante, sobre todo de niños sin enfermedad neurológica basal, presenta repercusión funcional clínicamente significativa al alta de UCIP y transcurrido un año. La repercusión en el pronóstico funcional del niño crítico apoya la importancia de la neuromonitorización y neuroprotección, medidas necesarias para mejorar la asistencia del niño crítico y la valoración evolutiva de la salud funcional


INTRODUCTION: Neurological diseases explain a considerable proportion of admissions to paediatric intensive care units (PICU), and are a significant cause of morbidity and mortality. This study aims to analyse the functional progression of children with critical neurological conditions. MATERIAL AND METHODS: Retrospective descriptive study of children admitted to PICU with neurological diseases over a period of 3 years (2012-2014), assessing vital and functional prognosis at PICU discharge and at one year according to the Pediatric Cerebral and Overall Performance Category scales (PCPC-POPC) and the Functional Status Scale (FSS). The results are compared with our previous data (1990-1999), and those of the international multicentre PANGEA study. RESULTS: A total of 266 children were studied. The mortality rate was 3%; the PRISM-III and PIM2 models did not show predictive ability. Clinically significant worsening was observed in functional health at discharge in 30% of the sample, according to POPC, 15% according to PCPC, and 5% according to FSS. After one year, functional performance improved according to PCPC-POPC, but not according to FSS. Children with no underlying neurological disease had a higher degree of functional impairment; this was prolonged over time. We observed a decrease in overall and neurocritical mortality compared with our previous data (5.60 vs. 2.1%, P = .0003, and 8.44 vs. 2.63%, P = .0014, respectively). Compared with the PANGEA study, both mortality and cerebral functional impairment in neurocritical children were lower in our study (1.05 vs. 13.32%, P < .0001, and 10.47% vs. 23.79%, P < .0001, respectively). CONCLUSIONS: Nearly one-third of critically ill children have neurological diseases. A significant percentage, mainly children without underlying neurological diseases, had a clinically significant functional impact at PICU discharge and after a year. Neuromonitoring and neuroprotection measures and the evaluation of functional progression are necessary to improve critical child care


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Unidades de Terapia Intensiva Pediátrica , Doenças do Sistema Nervoso/fisiopatologia , Doenças do Sistema Nervoso/mortalidade , Estado Terminal/terapia , Mortalidade Hospitalar , Estudos Retrospectivos , Prognóstico
9.
Neurología (Barc., Ed. impr.) ; 35(5): 311-317, jun. 2020. tab
Artigo em Espanhol | IBECS | ID: ibc-197539

RESUMO

INTRODUCCIÓN: La salud funcional, parámetro adecuado de morbilidad, debería constituir un estándar pronóstico de las unidades de cuidados intensivos pediátricos (UCIP), siendo fundamental el desarrollo de escalas para su valoración. Las categorías de estado global y cerebral pediátrico (CEGP-CECP) se han empleado clásicamente en estudios pediátricos; el desarrollo de la nueva Escala de estado funcional (FSS) busca mejorar la objetividad. El objetivo del trabajo es comprobar si la escala FSS es un instrumento válido frente a la clásica CEGP-CECP, y si, incluso, posee mejores cualidades evaluadoras de la funcionalidad neurológica. PACIENTES Y MÉTODO: Estudio retrospectivo descriptivo de los 266 niños con enfermedad neurológica ingresados en la UCIP durante 3 años (2012-2014). Se valora su salud funcional al alta y tras un año del ingreso en UCIP, según las categorías CEGP-CECP y la nueva FSS, comparando ambas escalas mediante análisis de correlación (Rho de Spearman). RESULTADOS: La comparación de varianzas de FSSglobal en cada intervalo de CEGP muestra buena correlación para todas las comparaciones (p < 0,001), excepto en la categoría «5 = coma-vegetativo». La dispersión de FSSglobal aumenta a medida que lo hace la categoría CEGP. La correlación es similar en la versión neurológica de ambas escalas. DISCUSIÓN: La nueva escala FSS parece ser un método útil para evaluar salud funcional en nuestro medio, tras su comparación con las clásicas categorías CEGP-CECP. La dispersión de los valores de la escala FSS indica falta de precisión del sistema CEGP-CECP, comparado con la nueva escala FSS, más desglosada y objetiva


INTRODUCTION: Functional health, a reliable parameter of the impact of disease, should be used systematically to assess prognosis in paediatric intensive care units (PICU). Developing scales for the assessment of functional health is therefore essential. The Paediatric Overall and Cerebral Performance Category (POPC, PCPC) scales have traditionally been used in paediatric studies. The new Functional Status Scale (FSS) was designed to provide more objective results. This study aims to confirm the validity of the FSS compared to the classic POPC and PCPC scales, and to evaluate whether it may also be superior to the latter in assessing of neurological function. PATIENTS AND METHOD: We conducted a retrospective descriptive study of 266 children with neurological diseases admitted to intensive care between 2012 and 2014. Functional health at discharge and at one year after discharge was evaluated using the PCPC and POPC scales and the new FSS. RESULTS: Global FSS scores were found to be well correlated with all POPC scores (P < .001), except in category 5 (coma/vegetative state). Global FSS score dispersion increases with POPC category. The neurological versions of both scales show a similar correlation. DISCUSSION: Comparison with classic POPC and PCPC categories suggests that the new FSS scale is a useful method for evaluating functional health in our setting. The dispersion of FSS values underlines the poor accuracy of POPC-PCPC compared to the new FSS scale, which is more disaggregated and objective


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Unidades de Terapia Intensiva Pediátrica , Doenças do Sistema Nervoso/terapia , Avaliação das Necessidades , Modalidades de Fisioterapia , Hospitalização , Tempo de Internação , Estudos Retrospectivos , Espanha
10.
Neurologia (Engl Ed) ; 35(5): 311-317, 2020 Jun.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29102527

RESUMO

INTRODUCTION: Functional health, a reliable parameter of the impact of disease, should be used systematically to assess prognosis in paediatric intensive care units (PICU). Developing scales for the assessment of functional health is therefore essential. The Paediatric Overall and Cerebral Performance Category (POPC, PCPC) scales have traditionally been used in paediatric studies. The new Functional Status Scale (FSS) was designed to provide more objective results. This study aims to confirm the validity of the FSS compared to the classic POPC and PCPC scales, and to evaluate whether it may also be superior to the latter in assessing of neurological function. PATIENTS AND METHOD: We conducted a retrospective descriptive study of 266 children with neurological diseases admitted to intensive care between 2012 and 2014. Functional health at discharge and at one year after discharge was evaluated using the PCPC and POPC scales and the new FSS. RESULTS: Global FSS scores were found to be well correlated with all POPC scores (P<.001), except in category 5 (coma/vegetative state). Global FSS score dispersion increases with POPC category. The neurological versions of both scales show a similar correlation. DISCUSSION: Comparison with classic POPC and PCPC categories suggests that the new FSS scale is a useful method for evaluating functional health in our setting. The dispersion of FSS values underlines the poor accuracy of POPC-PCPC compared to the new FSS scale, which is more disaggregated and objective.


Assuntos
Unidades de Terapia Intensiva Pediátrica , Doenças do Sistema Nervoso/terapia , Avaliação de Resultados em Cuidados de Saúde , Modalidades de Fisioterapia , Pré-Escolar , Feminino , Hospitalização , Humanos , Tempo de Internação , Masculino , Estudos Retrospectivos , Espanha
11.
Neurologia (Engl Ed) ; 35(6): 381-394, 2020.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29174722

RESUMO

INTRODUCTION: Neurological diseases explain a considerable proportion of admissions to paediatric intensive care units (PICU), and are a significant cause of morbidity and mortality. This study aims to analyse the functional progression of children with critical neurological conditions. MATERIAL AND METHODS: Retrospective descriptive study of children admitted to PICU with neurological diseases over a period of 3 years (2012-2014), assessing vital and functional prognosis at PICU discharge and at one year according to the Pediatric Cerebral and Overall Performance Category scales (PCPC-POPC) and the Functional Status Scale (FSS). The results are compared with our previous data (1990-1999), and those of the international multicentre PANGEA study. RESULTS: A total of 266 children were studied. The mortality rate was 3%; the PRISM-III and PIM2 models did not show predictive ability. Clinically significant worsening was observed in functional health at discharge in 30% of the sample, according to POPC, 15% according to PCPC, and 5% according to FSS. After one year, functional performance improved according to PCPC-POPC, but not according to FSS. Children with no underlying neurological disease had a higher degree of functional impairment; this was prolonged over time. We observed a decrease in overall and neurocritical mortality compared with our previous data (5.60 vs. 2.1%, P=.0003, and 8.44 vs. 2.63%, P=.0014, respectively). Compared with the PANGEA study, both mortality and cerebral functional impairment in neurocritical children were lower in our study (1.05 vs. 13.32%, P<.0001, and 10.47% vs. 23.79%, P<.0001, respectively). CONCLUSIONS: Nearly one-third of critically ill children have neurological diseases. A significant percentage, mainly children without underlying neurological diseases, had a clinically significant functional impact at PICU discharge and after a year. Neuromonitoring and neuroprotection measures and the evaluation of functional progression are necessary to improve critical child care.


Assuntos
Unidades de Terapia Intensiva Pediátrica/estatística & dados numéricos , Doenças do Sistema Nervoso/terapia , Adolescente , Criança , Pré-Escolar , Cuidados Críticos/estatística & dados numéricos , Progressão da Doença , Feminino , Hospitalização , Humanos , Lactente , Recém-Nascido , Tempo de Internação , Masculino , Avaliação de Resultados em Cuidados de Saúde/estatística & dados numéricos , Alta do Paciente , Estudos Retrospectivos
12.
Neurologia (Engl Ed) ; 2019 Jul 17.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31326214

RESUMO

INTRODUCTION: Neurofibromatosis type 1 (NF1) is a progressive multisystem disorder following an autosomal dominant inheritance pattern that presents with multiple neurological manifestations. METHODS: We reviewed medical histories of patients with NF1 followed up at our hospital's paediatric neurology department from May 1990 to 31 December 2018. We collected data on neurological symptoms. RESULTS: A total of 128 patients with NF1 were identified. Mean age (SD) at NF1 diagnosis was 4.43 (3.38) years (range, 0.5-14.5 years). There was a slight female predominance (53.1%). Macrocephaly (head circumference over 2 SDs above average for age) was present in 37.5% of cases. Attention-deficit/hyperactivity disorder was recorded in 28.9% of patients (37): combined type in 20 patients, predominantly inattentive in 15, and predominantly impulsive/hyperactive in 2. Other manifestations included headache (18.6%), cognitive impairment (7.8%), motor deficit (6.2%), and epilepsy (4.68%). Brain MRI was performed in 85 patients, revealing T2-weighted hyperintensities in the basal ganglia and/or cerebellum in 60 patients (70.5%), Chiari malformation type 1 in 4 cases, and arachnoid cysts in 3. Optic nerve gliomas were identified by MRI in 22 patients (25.8%). Other MRI findings included plexiform neurofibromas (9.3%) and central nervous system gliomas (3.1%). CONCLUSIONS: The neurological manifestations identified in our sample are consistent with those reported in the literature. Effective transfer strategies from paediatric neurology departments and subsequent clinical follow-up by adult neurology departments are needed to prevent loss to follow-up in adulthood.

13.
Acta pediatr. esp ; 77(1/2): 24-33, ene.-feb. 2019. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-182871

RESUMO

Introducción: El cáncer es la primera causa de muerte por enfermedad en la infancia a partir del primer año de vida. En los últimos años ha mejorado la supervivencia de los pacientes, aunque esto contrasta con el desconocimiento de sus causas. Objetivo: Conocer los factores de riesgo, la incidencia, la epidemiología y la evolución del cáncer en niños de 0-14 años de edad residentes en Aragón y La Rioja entre 2002 y 2012. Analizar el conocimiento sobre la etiopatogenia del cáncer pediátrico. Pacientes y métodos: Estudio retrospectivo de 327 pacientes de 5 unidades de oncopediatría españolas. El Registro Nacional de Tumores Infantiles facilitó una serie de datos básicos de dichos casos; se estudiaron datos complementarios en los casos controlados en el Hospital Universitario Miguel Servet consultando los archivos del Servicio de Oncopediatría. Resultados: En los 327 pacientes hubo 338 casos nuevos, con una tasa de incidencia de 131 casos anuales por millón. El sexo predominante fue masculino. La mediana de tiempo desde el primer síntoma hasta el diagnóstico fue de 4 semanas. La incidencia tumoral por edad y tipo de neoplasia fue similar a la de la bibliografía revisada. Hubo 68 fallecidos (un 64,2% debido al cáncer como causa inmediata), y la supervivencia a los 5 años fue del 76,8%. Un total de 270 pacientes eran españoles y 20 extranjeros. De los españoles, 235 nacieron en Aragón, 28 en La Rioja y 7 en otra comunidad autónoma. El 28,6% residía en un ámbito rural en el momento del diagnóstico y el 71,4% en áreas urbanas, el 83,2% en Aragón y el 16,8% en La Rioja. En el 55,9% de los casos la familia estaba compuesta por 2 hijos, y en el 22,1% por 1 hijo. El paciente era el primogénito en el 47,2% de los casos


Introduction: Cancer is the leading cause of death by disease in children from the first year of life. The overall outlook for children with cancer has improved but the causes of most childhood cancers are still unknown. Objective: To know the risk factors, incidence, epidemiology and evolution of cancer among children aged 0-14 years living in Aragón and La Rioja between 2002-2012. Analyze the knowledge of the pathogenesis of pediatric cancer. Materials and methods: Retrospective study of 327 patients of 5 Oncopediatrics Units of Spain. The National Childhood Tumor Registry provided the basic data of these cases; the additional data were obtained from the files of the Oncopediatrics Unit in the Miguel Servet University Hospital. Results: There were 338 new cases and the incidence rate was of 131 cases per million with a predominance of male gender. The median time from first symptoms to diagnosis was 4 weeks. Cancer incidence was similar to the literature reviewed. There were 68 deaths (64.2% immediately due to cancer), the 5-year survival rate was of 76.8%. 270 patients were Spanish (235 were born in Aragón, 28 in La Rioja and 7 in other Autonomous Community) and 20 foreigners. At the time of diagnosis 28.6% lived in rural areas and 71.4% in urban areas (Aragón: 83.2%; La Rioja: 16.8%). The 55.9 percent of the families were composed of 2 children at diagnosis. The patient was the firstborn in the 47.2% of cases


Assuntos
Humanos , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Neoplasias/epidemiologia , Intervalo Livre de Doença , Estudos Retrospectivos , Espanha/epidemiologia , Incidência
14.
Ann Oncol ; 29(1): 170-177, 2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-29045543

RESUMO

Background: The presence of stromal tumor-infiltrating lymphocytes (TILs) is associated with increased pathologic complete response (pCR) and improved outcomes in HER2-positive early-breast cancer (BC) treated with anti-HER2-based chemotherapy. In the absence of chemotherapy, the association of TILs with pCR following anti-HER2 therapy-only is largely unknown. Patients and methods: The PAMELA neoadjuvant trial treated 151 women with HER2-positive BC with lapatinib and trastuzumab [and hormonal therapy if hormone receptor (HR)-positive] for 18 weeks. Percentage of TILs and tumor cellularity were determined at baseline (N = 148) and at day 15 (D15) of treatment (N = 134). Associations of TILs and tumor cellularity with pCR in the breast were evaluated. A combined score based on tumor cellularity and TILs (CelTIL) measured at D15 was derived in PAMELA, and validated in D15 samples from 65 patients with HER2-positive disease recruited in the LPT109096 neoadjuvant trial, where anti-HER2 therapy-only was administer for 2 weeks, then standard chemotherapy was added for 24 weeks. Results: In PAMELA, baseline and D15 TILs were significantly associated with pCR in univariate analysis. In multivariable analysis, D15 TILs, but not baseline TILs, were significantly associated with pCR. At D15, TILs and tumor cellularity were found independently associated with pCR. A combined score (CelTIL) taking into account both variables was derived. CelTIL at D15 as a continuous variable was significantly associated with pCR, and patients with CelTIL-low and CelTIL-high scores had a pCR rate of 0% and 33%, respectively. In LPT109096, CelTIL at D15 was found associated with pCR both as a continuous variable and as group categories using a pre-defined cut-off (75.0% versus 33.3%). Conclusions: On-treatment TILs, but not baseline TILs, are independently associated with response following anti-HER2 therapy-only. A combined score of TILs and tumor cellularity measured at D15 provides independent predictive information upon completion of neoadjuvant anti-HER2-based therapy. Clinical trial number: NCT01973660.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/imunologia , Linfócitos do Interstício Tumoral/imunologia , Modelos Biológicos , Receptor ErbB-2/antagonistas & inibidores , Idoso , Neoplasias da Mama/enzimologia , Neoplasias da Mama/patologia , Ensaios Clínicos Fase II como Assunto , Feminino , Humanos , Lapatinib/administração & dosagem , Linfócitos do Interstício Tumoral/patologia , Pessoa de Meia-Idade , Modelos Estatísticos , Estudos Multicêntricos como Assunto , Terapia Neoadjuvante , Valor Preditivo dos Testes , Ensaios Clínicos Controlados Aleatórios como Assunto , Receptor ErbB-2/metabolismo , Trastuzumab/administração & dosagem , Resultado do Tratamento
15.
Neurología (Barc., Ed. impr.) ; 32(7): 455-462, sept. 2017. tab
Artigo em Espanhol | IBECS | ID: ibc-166250

RESUMO

Objetivo: Estudio descriptivo de epilepsias sintomáticas, según edad de inicio, controladas en una Unidad de Neuropediatría de referencia regional durante 3 años. Pacientes y métodos: Niños con diagnóstico de epilepsia sintomática, controlados del 1 de enero del 2008 hasta el 31 de diciembre del 2010. Resultados: De 4595 niños en el periodo de estudio, recibieron el diagnóstico de epilepsia 605 (13,17%), siendo 277 (45,79%) epilepsias sintomáticas. Entre los pacientes que iniciaron la epilepsia por debajo del año de vida predominan las de etiología sintomática (67,72%). Entre los que la iniciaron entre 1-3 años, fueron sintomáticas el 61,39%. En cuanto a su etiología, ha sido: encefalopatías prenatales (24,46% del total de epilepsias), encefalopatías perinatales (9,26%), encefalopatías posnatales (3,14%), encefalopatías metabólicas y degenerativas (1,98%), esclerosis mesial temporal (1,32%), síndromes neurocutáneos (2,64%), malformaciones vasculares (0,17%), cavernomas (0,17%) y tumores intracraneales (2,48%). Algunas etiologías inician sus manifestaciones epilépticas por debajo del año de vida, como el síndrome de Down, la lisencefalia genética, la infección congénita por citomegalovirus, la encefalopatía hipóxico-isquémica, las encefalopatías metabólicas o la esclerosis tuberosa. Conclusiones: La ausencia de una clasificación universalmente aceptada de los síndromes epilépticos dificulta comparaciones entre series. Sugerimos que todas las epilepsias son sintomáticas puesto que tienen causa, genética o adquirida. La edad de inicio orienta a determinadas etiologías. Una clasificación útil es la etiológica, con 2 grupos: un gran grupo con las etiologías establecidas o síndromes genéticos muy probables y otro de casos sin causa establecida, que con los avances en neuroimagen y genética cada vez será menor (AU)


Objective: We conducted a descriptive study of symptomatic epilepsy by age at onset in a cohort of patients who were followed up at a neuropaediatric department of a reference hospital over a 3-year period. Patients and methods: We included all children with epilepsy who were followed up from January 1, 2008 to December 31, 2010. Results: Of the 4595 children seen during the study period, 605 (13.17%) were diagnosed with epilepsy; 277 (45.79%) of these had symptomatic epilepsy. Symptomatic epilepsy accounted for 67.72% and 61.39% of all epilepsies starting before one year of age, or between the ages of one and 3, respectively. The aetiologies of symptomatic epilepsy in our sample were: prenatal encephalopathies (24.46% of all epileptic patients), perinatal encephalopathies (9.26%), post-natal encephalopathies (3.14%), metabolic and degenerative encephalopathies (1.98%), mesial temporal sclerosis (1.32%), neurocutaneous syndromes (2.64%), vascular malformations (0.17%), cavernomas (0.17%), and intracranial tumours (2.48%). In some aetiologies, seizures begin before the age of one; these include Down syndrome, genetic lissencephaly, congenital cytomegalovirus infection, hypoxic-ischaemic encephalopathy, metabolic encephalopathies, and tuberous sclerosis. Conclusions: The lack of a universally accepted classification of epileptic syndromes makes it difficult to compare series from different studies. We suggest that all epilepsies are symptomatic because they have a cause, whether genetic or acquired. The age of onset may point to specific aetiologies. Classifying epilepsy by aetiology might be a useful approach. We could establish 2 groups: a large group including epileptic syndromes with known aetiologies or associated with genetic syndromes which are very likely to cause epilepsy, and another group including epileptic syndromes with no known cause. Thanks to the advances in neuroimaging and genetics, the latter group is expected to become increasingly smaller (AU)


Assuntos
Humanos , Lactente , Epilepsia/etiologia , Encefalopatias/complicações , Idade de Início , Epidemiologia Descritiva , Predisposição Genética para Doença , Lesão Encefálica Crônica/epidemiologia , Encefalopatias Metabólicas/epidemiologia , Meningite/epidemiologia
16.
Neurologia ; 32(7): 455-462, 2017 Sep.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27091679

RESUMO

OBJECTIVE: We conducted a descriptive study of symptomatic epilepsy by age at onset in a cohort of patients who were followed up at a neuropaediatric department of a reference hospital over a 3-year period PATIENTS AND METHODS: We included all children with epilepsy who were followed up from January 1, 2008 to December 31, 2010 RESULTS: Of the 4595 children seen during the study period, 605 (13.17%) were diagnosed with epilepsy; 277 (45.79%) of these had symptomatic epilepsy. Symptomatic epilepsy accounted for 67.72% and 61.39% of all epilepsies starting before one year of age, or between the ages of one and 3, respectively. The aetiologies of symptomatic epilepsy in our sample were: prenatal encephalopathies (24.46% of all epileptic patients), perinatal encephalopathies (9.26%), post-natal encephalopathies (3.14%), metabolic and degenerative encephalopathies (1.98%), mesial temporal sclerosis (1.32%), neurocutaneous syndromes (2.64%), vascular malformations (0.17%), cavernomas (0.17%), and intracranial tumours (2.48%). In some aetiologies, seizures begin before the age of one; these include Down syndrome, genetic lissencephaly, congenital cytomegalovirus infection, hypoxic-ischaemic encephalopathy, metabolic encephalopathies, and tuberous sclerosis. CONCLUSIONS: The lack of a universally accepted classification of epileptic syndromes makes it difficult to compare series from different studies. We suggest that all epilepsies are symptomatic because they have a cause, whether genetic or acquired. The age of onset may point to specific aetiologies. Classifying epilepsy by aetiology might be a useful approach. We could establish 2 groups: a large group including epileptic syndromes with known aetiologies or associated with genetic syndromes which are very likely to cause epilepsy, and another group including epileptic syndromes with no known cause. Thanks to the advances in neuroimaging and genetics, the latter group is expected to become increasingly smaller.


Assuntos
Idade de Início , Epilepsia/classificação , Epilepsia/etiologia , Neurologia , Pediatria , Encefalopatias/classificação , Criança , Pré-Escolar , Epilepsia/genética , Feminino , Seguimentos , Humanos , Lactente , Masculino , Estudos Retrospectivos
17.
Rev Neurol ; 63(10): 447-454, 2016 Nov 16.
Artigo em Espanhol | MEDLINE | ID: mdl-27819402

RESUMO

AIM: A descriptive study of non-symptomatic epilepsy (idiopathic and cryptogenic), according to age at onset, monitored at a Neuropediatric Section of regional reference over a period of three years. PATIENTS AND METHODS: A review of neuropediatric database medical records of children with non-symptomatic epilepsy supervised from Jan 1, 2008 till December 31, 2010. RESULTS: Of the 4595 children attended during the period, 605 were diagnosed with epilepsy (13.17%): 156 (25.79%) idiopathic epilepsies and 172 (28.43%) cryptogenic epilepsies. The average age at onset of the total was 4.78 years: 6.31 years in idiopathic epilepsies and 5.43 years in cryptogenic epilepsies. 26.12% of all the epilepsies began in the first year of life. Idiopathic epilepsy predominates in the startup group of 6-10 years and cryptogenic epilepsy in 3-6 years. Absence epilepsy and benign childhood epilepsy with centro-temporal spikes are the idiopathic epileptic syndromes most prevalent. CONCLUSIONS: Many differences exist among published epidemiological data on childhood epilepsy due to the difficulty of a syndromic diagnosis in children, caused by clinical and electroencephalographic variability. The absence of a universally accepted classification of epileptic syndromes makes it difficult to compare publications. All epilepsies are symptomatic as they have a cause, whether it be genetic or acquired. A useful classification would be etiological, with two groups: one large with established etiology or very likely genetic syndromes and another with no established cause. The age at onset indicates specific etiologies.


TITLE: Estudio descriptivo de las epilepsias no sintomaticas segun la edad de inicio en una unidad de neuropediatria de referencia regional.Objetivo. Estudio descriptivo de las epilepsias no sintomaticas (idiopaticas y criptogenicas), segun la edad de inicio, controladas en una unidad de neuropediatria de referencia regional durante tres años. Pacientes y metodos. Revision de historias de niños con epilepsia no sintomatica de la base de datos de neuropediatria controlados del 1 de enero de 2008 al 31 de diciembre de 2010. Resultados. De 4.595 niños atendidos en el periodo, se diagnosticaron de epilepsia 605 (13,17%), de las cuales 156 (25,79%) fueron idiopaticas, y 172 (28,43%), criptogenicas. La edad media de inicio del total fue de 4,78 años; 6,31 años en las idiopaticas y 5,43 años en las criptogenicas. El 26,12% del total de epilepsias se inicio en el primer año. Las epilepsias idiopaticas predominan en el grupo de inicio de 6-10 años, y las criptogenicas, en el de 3-6 años. La epilepsia de ausencias y la epilepsia benigna de la infancia con paroxismos centrotemporales son los sindromes epilepticos idiopaticos mas prevalentes. Conclusiones. Existen muchas diferencias de datos epidemiologicos publicados sobre epilepsia infantil por la dificultad que entraña un diagnostico sindromico en la edad pediatrica, debido a la variabilidad clinica y electroencefalografica. La ausencia de una clasificacion universalmente aceptada de los sindromes epilepticos dificulta comparaciones entre series. Todas las epilepsias son sintomaticas, puesto que tienen causa, sea genetica o adquirida. Una clasificacion util es la etiologica, con dos grupos: un gran grupo con las etiologias establecidas o sindromes geneticos muy probables y otro de casos sin causa establecida. La edad de inicio orienta a determinadas etiologias.


Assuntos
Idade de Início , Epilepsia Tipo Ausência/epidemiologia , Epilepsia Rolândica/epidemiologia , Epilepsia/epidemiologia , Criança , Pré-Escolar , Eletroencefalografia , Humanos , Síndrome
18.
Breast Cancer Res Treat ; 151(3): 597-606, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25981896

RESUMO

Anthracycline and taxane-based primary chemotherapy (PCT) is the standard treatment for high-risk breast cancer (HRBC). However, conventional anthracyclines are not commonly used in elderly patients or those prone to cardiotoxicity. Pegylated liposomal doxorubicin, (PLD) has comparable efficacy, but less cardiotoxicity than conventional anthracyclines. We conducted a phase II single-arm trial to assess the efficacy and safety of PCT based on PLD followed by paclitaxel (PTX) in a HRBC population usually undertreated. Fifty patients with stage II-IIIB breast cancer and at least one risk factor for developing cardiotoxicity initiated PLD 35 mg/m(2) plus cyclophosphamide 600 mg/m(2) every 4 weeks for four cycles, followed by 80 mg/m(2) weekly PTX for 12. Close cardiac monitoring was performed. Primary endpoint was the pathological complete response rate (pCR) in the breast. Treatment delivery and toxicities were assessed. Eighty-four per cent of patients were older than 65 years, 64 % suffered from hypertension, and 10 % had prior cardiac disease. In an intention-to-treat analysis, breast pCR was 32 % (95 % CI 19.5-46.7 %) and pCR in breast and axilla was 24 % (95 % CI 12.1-35.8 %). At diagnosis only, 26 % of patients were candidates for breast conservative surgery, which increased to 58.7 % after PCT. No significant decrease in left ventricular ejection fraction was seen. PLD followed by PTX was feasible in a fragile population of patients who were not candidates for conventional doxorubicin. Moreover, it achieved a pCR similar to standard therapy and could therefore be an option for elderly patients or cardiotoxicity-prone who present HRBC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Biomarcadores Tumorais , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Cardiotoxicidade , Comorbidade , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Doxorrubicina/análogos & derivados , Feminino , Cardiopatias/diagnóstico , Cardiopatias/etiologia , Cardiopatias/fisiopatologia , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Paclitaxel/administração & dosagem , Polietilenoglicóis/administração & dosagem , Fatores de Risco , Resultado do Tratamento
19.
Rev. esp. pediatr. (Ed. impr.) ; 70(4): 189-193, jul.-ago. 2014. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-128377

RESUMO

Introducción. La auscultación de un soplo constituye con frecuencia el principal motivo de consulta en Cardiología Pediátrica. Un pequeño porcentaje de pacientes (0.8-1%) presentan cardiopatía estructural; entre los defectos más graves, la morbimortalidad continúa siendo elevada, recomendándose la evaluación ecocardiográfica ante la sospecha de patología. Material y métodos. Estudio retrospectivo descriptivo de 1.529 niños entre 0 y 16 años atendidos en la consulta de Cardiología del Hospital Clínico Universitario Lozano Blesa, de Zaragoza, entre enero de 2010 y diciembre de 2012. Se analizaron los hallazgos más frecuentes de la muestra y cada grupo de edad. Resultados. El principal motivo de consulta fue la auscultación de un soplo, el 43,4% (649) de los pacientes procedían de Atención Primaria. Los hallazgos más frecuentes fueron los defectos del tabique intraventricular en un 6,5% (99), interauricular 5,8% (89%) y las valvulopatías 5,2% (80). Entre los neonatos se evidenció patología en el 5.2% (80). Entre los neonatos se evidenció patología en el 65,4% (208) frente al 16,7% (112) de los escolares. Conclusiones. La mayoría de los pacientes son remitidos desde Atención Primaria, siendo el principal motivo de consulta la auscultación de un soplo. En un porcentaje elevado de casos la ecocardiografía es normal, siendo frecuente el diagnóstico de soplo inocente, especialmente entre los pacientes de mayor edad (AU)


Introduction. The finding of an innocent murmur in the child frequently represents the first cause to consult in Cardiology. A small percentage of patients (0.8-1%) presents a congenital heart disease; between the severest defects, the morbimortality continues being high, which leads to tecommend the ecochardiografic evaluation due to suspicion of disease. Material and methods. A descriptive research of 1529 patients between 0 to 16 years old assessed at the Paediatric Cardiology consult at the Hospital Clínico Universitario Lozano Blesa in Zaragoza between January 2010 to December 2012. The most frequent findings were analized from the whole and each age group. Outcomes. The first cause to consult was the finding of a murmur with the stethoscope; 42,4% (649) of the patients came from Primary Attention. The principal findings were the ventricular septal defects in 6,5% (99), atrial septal defects 5,8% (89)and the valvulopathies 5,2% (80). There was pathology in the 65.4% (208) between neonates, but in the 16,7 (112) between the schoolchildren. Conclusions. Most of the patients came from Primary Attention, due to the finding of a murmur. In a high percentage the echocardiography is normal, the diagnostic of an innocent murmur is frequent specially in the oldest age range (AU)


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Cardiopatias/epidemiologia , Ecocardiografia/métodos , Ecocardiografia , Doenças das Valvas Cardíacas/epidemiologia , Doenças das Valvas Cardíacas/prevenção & controle , Auscultação/métodos , Auscultação , Auscultação Cardíaca , Estudos Retrospectivos , Indicadores de Morbimortalidade , Atenção Primária à Saúde/métodos , Atenção Primária à Saúde
20.
Neurología (Barc., Ed. impr.) ; 29(1): 36-41, ene.-feb. 2014. tab
Artigo em Espanhol | IBECS | ID: ibc-119378

RESUMO

Objetivo: El objetivo de este trabajo es conocer el perfil de la demanda asistencial neuropediátrica en un hospital español de tercer nivel a lo largo de los últimos 20 años. Método: Se estudiaron datos epidemiológicos, motivos de consulta, diagnósticos y exámenes complementarios de todos los pacientes valorados en nuestra Unidad de Neuropediatría en sus 20 años de funcionamiento (de mayo de 1990 a marzo del 2010). También se revisaron estos mismos datos centrándonos en pacientes cuya primera visita se efectuó en los últimos 5 años (2005-2010), para compararlos con los obtenidos en un estudio previo desarrollado de 1990 a 1995 en esta unidad. Para comparar los 5 primeros años (grupo 1) con los últimos 5 años (grupo 2), se calcularon los intervalos de confianza para p < 0,05 para la distribución en frecuencias (%) de cada categoría. Resultados: Los principales motivos de consulta y diagnósticos de los 12.726 pacientes valorados en los 20 años, así como los resultados obtenidos del grupo 1 (2.046 pacientes) y del grupo 2 (4.488 pacientes), con sus intervalos de confianza, se presentan en diversas tablas. Conclusiones: Las variaciones experimentadas en los motivos de consulta, los diagnósticos y los exámenes complementarios a lo largo del tiempo reflejan los cambios determinados por los avances médicos, científicos y sociales, además de temas organizativos propios de cada hospital, lo que explica las dificultades para comparar diferentes series de pacientes en diferentes momentos y más aún entre diferentes hospitales


Objective: The purpose of this study is to determine the profile of the demand for paediatric neurology care in a Spanish tertiary hospital over the past 20 years. Method: We studied epidemiological data, reasons for consultation, diagnoses and complementary tests from all patients examined by our Paediatric Neurology Unit in its 20 years of service (from May 1990 to March 2010). We also reviewed data from patients whose first visit took place within the last five years (2005-2010) and compared them to data obtained from a prior study carried out in this Unit from 1990 to 1995. To compare the first 5 years (group 1) with the last 5 years (group 2), we calculated confidence intervals, P<.05, for the frequency distribution (%) in each category. Results: Main reasons for consultation and principal diagnoses for the 12726 patients evaluated in the 20-year period, as well as results from group 1 (2046 patients) and group 2 (4488 patients) corresponding to first and the last 5 years of activity respectively, are presented with their confidence intervals in a series of tables. Conclusions: Variations in the reasons for consultation, diagnoses and complementary tests over time reflect changes determined by medical, scientific and social progress, and organizational changes specific to each hospital. This explains the difficulty of comparing different patient series studied consecutively, which are even more pronounced between different hospitals


Assuntos
Humanos , Masculino , Feminino , Criança , Transtornos Globais do Desenvolvimento Infantil/epidemiologia , Transtorno Autístico/epidemiologia , Doenças do Sistema Nervoso/epidemiologia , Serviços de Saúde da Criança/estatística & dados numéricos , Doenças Raras/epidemiologia , Transtornos Psicomotores/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...